Bringing the very best science and medicine to our best equine friends

NEWS

Kindred Biosciences Submits Zimeta (KIND-012) New Animal Drug Application Technical Section for Effectiveness to FDA

San Francisco, CA (February 11, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Effectiveness Technical Section of the New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012). Positive topline results from the pivotal field study (KB0120) of Zimeta for the control of pyrexia (fever) in horses were recently reported by the Company. The Chemistry, Manufacturing, and Controls technical section for Zimeta was submitted in December 2015 and all remaining technical sections of the NADA are planned for submission by the end …

Continue Reading

Kindred Biosciences Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

Monday, January 11, 2016 Time of Event: 8:30 AM Eastern Standard Time Webcast URL: http://edge.media-server.com/m/p/sfos7gz9  For more information on this event, please see the press release

Continue Reading

Kindred Biosciences to Provide Corporate Update via Webcast in Advance of One-on-One Investor Meetings in San Francisco January 12-14, 2016.

San Francisco, CA (January 7, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will provide a corporate update via webcast on Monday, January 11, 2016 in advance of one-on-one investor meetings in San Francisco January 12-14, 2016.

Continue Reading

Kindred Biosciences Submits KIND-012 New Animal Drug Application Technical Section for Chemistry, Manufacturing, and Controls to FDA

San Francisco, CA (December 17, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application (NADA) for KIND-012. Positive topline results from the pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses were recently reported by the Company. All technical sections of the NADA for KIND-012 are planned for submission by the end of the first quarter of 2016. Richard Chin, M.D., President and CEO of …

Continue Reading

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-012 for Pyrexia in Horses, and Provides Other Product Updates

KIND-012 study meets primary endpoint with p<0.0001. Data to be filed with the FDA for approval. SentiKind study misses primary endpoint. Conference call and webcast scheduled for 5:00 p.m. Eastern Time today. San Francisco, CA (November 16, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses.

Continue Reading

Kindred Biosciences Announces Third Quarter 2015 Financial Results

San Francisco, CA (November 9, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the third quarter ended September 30, 2015 and provided updates on its programs. Development and Corporate Updates KindredBio continues to advance a diversified portfolio of molecules in a capital efficient manner. Some of the recent highlights include: SentiKind™, or KIND-090, pivotal study. The pivotal field study of SentiKind, a KCNQ potassium channel agonist for post-operative pain in dogs, completed enrollment and the Company plans to report topline results in the coming weeks. The Chemical, Manufacturing, and Controls (CMC) and Target Animal Safety Study (TASS) …

Continue Reading

Kindred Biosciences Announces Second Quarter 2015 Financial Results

San Francisco, CA (August 10, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the second quarter ended June 30, 2015 and provided updates on its programs. Development and Corporate Updates KindredBio continues to advance a diversified portfolio of validated molecules in a capital efficient manner and has over 20 programs in development. Some of the recent highlights include: Completion of enrollment in SentiKind™ pivotal study. The pivotal field trial of SentiKind, a KCNQ potassium channel agonist for post-operative pain in dogs, recently completed enrollment and the Company plans to report topline results before the end of this …

Continue Reading